Home » Trials » SLCTR/2018/021 » Protocols
Date
2019-01-28
Protocol
No protocol changes
Item Changed
Secondary outcome(s) - Time 0f assessment(s)
Previous Version
At baseline, and then every 12 weeks for a total of 24 weeks. Secondary outcome 3 (hypersensitivity) will be assessed at the time of administration.
Next Version
Secondary outcome(s) Rate of decline of GFR [At baseline, and then every 12 weeks for a total of 24 weeks. ] Reduction of urine Cd level (cadmium, heavy metal) [At baseline, and then every 12 weeks for a total of 24 weeks. ] Safety outcomes – acute hypersensitivity reactions measured by clinical observation. [Assessed at the time of administration. ]